Alzheimer's Association will fund $1.5 mil. in biomedical research from Cognex royalty fund.
ALZHEIMER's ASSN. TO FUND $1.5 MIL. OF RESEARCH VIA COGNEX ROYALTY FUND, according to the association's recent request for proposals. The RFP seeks biomedical research projects addressing the results of biological or pharmacological interventions for Alzheimer's disease. An earlier RFP offered $1.4 mil. in funding for psychosocial research projects. Funding for both programs will be provided through the "tacrine royalty fund," a royalty agreement based on the sales of Warner-Lambert's Cognex and administered by the Alzheimer's Association.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth